Skip to main content

Market Overview

Lexaria Bioscience's Formulated Cannabidiol Lowers Blood Pressure In Hypertension Patients

Share:
Lexaria Bioscience's Formulated Cannabidiol Lowers Blood Pressure In Hypertension Patients
  • Lexaria Bioscience Corp (NASDAQ: LEXX) has announced initial results from human clinical study HYPER-H21-2 evaluating DehydraTECH-processed cannabidiol (CBD) for potential application against hypertension. 
  • Related Content: DehydraTECH Delivered Colchicine Can Potentially Treat COVID-19, Side Effects From mRNA Shots.
  • At selected times during the 24-hour study, volunteers with mild to moderate hypertension averaged as much as a 20 mmHg (i.e., 23%) decrease in blood pressure (BP) relative to placebo.
  • Over the 24-hour ambulatory monitoring period, volunteers averaged a significant reduction of 7.0% in systolic pressure with DehydraTECH-CBD relative to placebo.
  • Over the 24-hour ambulatory monitoring period, volunteers averaged a significant reduction of 5.3% in mean arterial pressure (MAP) with DehydraTECH-CBD relative to placebo.
  • Over the 24-hour ambulatory monitoring period, volunteers averaged a significant reduction of 3.5% in diastolic pressure relative to an increase in diastolic pressure (-0.8 vs. +2.7) from baseline with DehydraTECH-CBD relative to placebo.
  • Data analysis from the study is continuing, and additional outcomes will be reported upon when complete.
  • Read Next: Lexaria's R&D Program Reveals 5 Exciting Results Within 2 Months.
  • Price Action: LEXX shares are up 15.1% at $7.25 during the premarket session on the last check Tuesday.
 

Related Articles (LEXX)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech Long Ideas News Health Care Movers Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com